The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia
Open accessAbstract
Sum m a r yHypoxia-inducible factors are transcription factors controlling energy, iron metabolism, erythropoiesis, and development.When these proteins are dysregulated, they contribute to tumorigenesis and cancer progression.However, mutations in genes encoding α subunits of hypoxia-inducible factors (HIF-α) have not previously been identified in any cancer.Here we report two novel somatic gain-of-function mutations in the gene encoding hypoxia-inducible factor 2α (HIF2A) in two patients, one presenting with paraganglioma and the other with paraganglioma and somatostatinoma, both of whom had polycythemia.The two mutations were associated with increased HIF-2α activity and increased protein half-life.H ypoxia-inducible factors, originally described by Wang et al., 1 are transcription factors that respond to changes in tissue oxygen concentration.These highly conserved proteins are composed of α and β subunits.The HIF-β subunit is constitutively expressed, whereas the α subunits are inducible by hypoxia and are associated with aggressive, treatment-refractory tumors.2,3 Under normoxic conditions, HIF-1α, HIF-2α, and HIF-3α are hydroxylated on specific prolyl residues, allowing for recognition by the von Hippel-Lindau (VHL) tumorsuppressor protein, ubiquitination, and rapid degradation through the proteasome.4 Under hypoxic conditions, prolyl hydroxylation of HIF-α proteins is reduced, resulting in their stabilization and, in turn, transcription of genes involved in the hypoxia response, including angiogenesis, glycolysis, apoptosis, proliferation, and growth.5,6 Paragangliomas and pheochromocytomas are catecholamine-producing tumors derived from the chromaffin cells of extraadrenal paraganglia and the adrenal medulla.7 The pioneering work of Neumann et al. 8 showed that about one fourth of these tumors were hereditary, a fraction that was subsequently estimated to be closer to one third, on the basis of the identification of mutations in several additional genes, including SDHA, SDHAF2, TMEM127, and MAX. 9 The identification of these genetic drivers led to the demonstration of HIF-α stabilization and dysregulation in paragangliomas and pheochromocytomas harboring mutations in VHL and succinate dehydrogenase (SDH).10,11 Somatostatinomas are somatostatin-producing neuroendocrine tumors believed to originate from neural-crest cells.They are occasionally diagnosed in patients with the VHL syndrome, multiple endocrine neoplasia type 1 or 2, or neurofibromatosis type 1. 12
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Somatic gain-of-function mutations in HIF2A have been discovered in pheochromocytomas and paragangliomas (Zhuang et al., 2012;Comino-Mendez et al., 2013;Lorenzo et al., 2013;Taieb et al., 2013;Toledo et al., 2013;Yang et al., 2013), while high HIF-2α expression is associated with poor survival in patients with neuroblastoma (Holmquist-Mengelbier et al., 2006).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Zhuang et al., 2012
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Lenders, J. W. M., Eisenhofer, G., Mannelli, M., & Pacák, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,541
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,350
The role of hypoxia-inducible factors in tumorigenesis
Rankin, E. B., & Giaccia, A. J. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.21 · Cited by 806
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192342099 · Cited by 561
HIF-2α, but not HIF-1α, promotes iron absorption in mice
Mastrogiannaki, M., Matak, P., Keith, B., Simon, M. C., Vaulont, S., & Peyssonnaux, C. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38499 · Cited by 502
Clifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma
Ladroue, C., Carcenac, R., Leporrier, M., Gad, S., Le Hello, C., Galateau-Salle, F., Feunteun, J., Pouysségur, J., Richard, S., & Gardie, B. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806277 · Cited by 323
A Gain-of-Function Mutation in the HIF2A Gene in Familial Erythrocytosis
Percy, M. J., Furlow, P. W., Lucas, G. S., Li, X., Lappin, T. R. J., McMullin, M. F., & Lee, F. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073123 · Cited by 314
An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes
Gimenez‐Roqueplo, A., Dahia, P. L. M., & Robledo, M. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0031-1301302 · Cited by 289
The Warburg effect is genetically determined in inherited pheochromocytomas
Favier, J., Brière, J.-J., Burnichon, N., Rivière, J., Vescovo, L., Benit, P., Giscos-Douriez, I., De Reyniès, A., Bertherat, J., Badoual, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007094 · Cited by 232
Kaelin, W. G. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010975 · Cited by 161
Somatostatinomas, PPomas, neurotensinomas.
Vinik, A. I., Strodel, W. E., Eckhauser, F. E., Moattari, A. R., & Lloyd, R. V. (1987) · PubMed · Cited by 105
Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
Morris, M. R., Hughes, D. J., Tian, Y.-M., Ricketts, C. J., Lau, K. W., Gentle, D., Shuib, S., Serrano‐Fernández, P., Lubiński, J., Wiesener, M. S., et al. (2009) · PubMed · Cited by 58
Comparative Proteomic Profiles of Meningioma Subtypes
Okamoto, H., Li, J., Vortmeyer, A. O., Jaffe, H., Lee, Y., Gläsker, S., Sohn, T.-S., Zeng, W., Ikejiri, B. L., Proescholdt, M. A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0955 · Cited by 45
Self-citation(2008) · PubMed · Cited by 26
The HIF2A gene in familial erythrocytosis.
Prchal, J. T., & Gordeuk, V. R. (2008) · PubMed · Cited by 13
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Vinik AI, 1987, Semin Oncol, 14, 263
- Morris MR, 2009, Anticancer Res, 29, 4337
- Prchal JT, 2008, N Engl J Med, 358, 1966
Cited by
Sorted by citations
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Fishbein, L. M., Leshchiner, I., Walter, V., Danilova, L., Robertson, A. G., Johnson, A. R., Lichtenberg, T. M., Murray, B. A., Ghayee, H. K., Else, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.001 · Cited by 810
Regulation of erythropoiesis by hypoxia-inducible factors
Haase, V. H. (2013) · Blood Reviews · doi:10.1016/j.blre.2012.12.003 · Cited by 787
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“Somatic gain-of-function mutations in HIF2A have been discovered in pheochromocytomas and paragangliomas (Zhuang et al., 2012; Comino-Mendez et al., 2013; Lorenzo et al., 2013; Taieb et al., 2013; Toledo et al., 2013; Yang et al., 2013), while high HIF-2α expression is associated with poor survival…”
BackgroundNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E. K., Blaszkowsky, L. S., Brock, P. L., Chan, J., Das, S., Dickson, P. V., Fanta, P. T., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 642
Metadata
- Authors
- Zhuang, Z., Yang, C., Lorenzo, F., Merino, M., Fojo, T., Kebebew, E., Popovic, V., Stratakis, C. A., Prchal, J. T., & Pacak, K.
- Affiliations
- National Institutes of Health (US)
- National Institute of Neurological Disorders and Stroke (US)
- Veterans Health Administration (US)
- National Cancer Institute (MY)
- National Cancer Institute (UA)
- University of Belgrade (RS)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- University of Utah (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-09-06
- Volume
- 367
- Issue
- 10
- Pages
- 922-930
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3432945
- OpenAlex
- W2142033642
- Cited by
- 397
- References
- 26
- Citations by year
- 2026: 22 · 2025: 12 · 2024: 22 · 2023: 18 · 2022: 20 · 2021: 29 · 2020: 24 · 2019: 24 · 2018: 32 · 2017: 43 · 2016: 27 · 2015: 31 · 2014: 47 · 2013: 42 · 2012: 2
- FWCI
- 39.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (P01CA108671)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIAHD008735)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- HIF-2α, paraganglioma, polycythemia, somatostatinoma, gain-of-function mutations, protein half-life, prolyl hydroxylation, VHL, succinate dehydrogenase, pheochromocytoma
- MeSH terms
- Abdominal Neoplasms, Endothelial PAS Domain-Containing Protein 1, Adolescent, Adrenal Gland Neoplasms, Adult, DNA Mutational Analysis, Female, Humans, Hydroxylation, Mutation, Pancreatic Neoplasms, Paraganglioma, Polycythemia, Somatostatinoma, Transcription, Genetic, Up-Regulation, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
